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Abstract
Human monocyte subsets, isolated from cultures of mononuclear cells, or freshly obtained from patients with multiple
sclerosis, Graves‘ disease or pemphigus vulgaris, differed in phenotype, apoptotic features, mRNA levels of arginase II (A-II)
and the inducible form of nitric oxide synthase (iNOS). Liver-type arginase I mRNA was present in all subsets. Apoptosis
was followed by the expression of T cell intracellular antigen (TIA) and the simultaneous detection of DNA stainability by
propidium iodine and annexin V binding. Apoptosis was practical ly absent both in activated
CD14CD33DRCD25CD69CD71=CD163 cells, expressing A-II mRNA and having arginase activity, but
not iNOS mRNA, and in not fully mature large CD14CD16CD23DR monocytes, expressing simultaneously
both mRNAs and having both enzyme activities. However, differentiated small CD14=CD16CD69-
CD25=3CD71CD23DR monocytes, expressing high levels of iNOS mRNA, exhibited apoptotic signs. Amounts
of NO synthesised by monocytes co-expressing iNOS and arginase changed with the addition of arginine or an iNOS
inhibitor; in that case a correlation of NO production and apoptotic features was observed. Data suggest a regulatory role
for endogenous NO in apoptosis of stimulated and differentiated monocytes, and also that iNOS and A-II, when
simultaneously present, could control the production of NO as a consequence of their competition for arginine. ß 1999
Elsevier Science B.V. All rights reserved.
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1. Introduction
Nitric oxide synthase (iNOS) and arginases are
expressed in murine macrophages [1^3]. Arginase I
(A-I) plays a critical role in liver metabolism as a key
component of the urea cycle; however, this enzyme is
also present in tissues where the urea cycle is not
operating. On the other hand many extrahepatic tis-
sues contain a second form of arginase, arginase II
(A-II), involved in the metabolism of nitric oxide
[4,5]. It has been reported that LPS induces rat peri-
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toneal macrophage expression of iNOS and liver-
type A-I [1] ; and A-II and iNOS mRNAs are co-
induced in murine macrophage-like RAW 264.7 cells
by LPS [2,6]. Arginases and iNOS are controlled in
macrophages by Th1/Th2-dependent cytokines [7,8].
Arginase expression in murine bone marrow-derived
macrophages is speci¢cally triggered by PGE2 and
Th2 cytokines IL-4, IL-10; in contrast, Th1 cytokine
IFN-Q induces NO synthesis, but arginase is not ex-
pressed under those conditions [7]. The simultaneous
presence of both types of mediators leads to a re-
duced expression of iNOS and arginase, enzymes
which seem to de¢ne alternate functional states of
macrophages induced by Th1 and Th2 cytokines re-
spectively [8].
A human-type A-II arginase is expressed in extra-
hepatic tissues and regulated both tissue speci¢cally
and developmentally [5] ; it has been suggested that
this enzyme plays some important role in the argi-
nine regulatory system encompassing several en-
zymes, among them nitric oxide synthase [9]. We
have described iNOS induction in human monocytes,
when PBMC from healthy donors are incubated in
the presence of an immunomodulating 15 amino acid
peptide, peptide Pa, (NVLGAPKKLNESQAV) [10]
capable of activating monocytes [11], and inducing
Th1 cytokine liberation [12]. We have also reported
that monocytes, freshly obtained from patients with
multiple sclerosis [13] or Graves’ disease [14], have
iNOS already expressed in a monocyte subset with
high levels of HLA-DR molecule expression and ex-
hibiting a CD16 phenotype characteristic of a state
of di¡erentiation [13]; this iNOS expression depends
on the liberation of Th1 cytokines, IFN-Q and IL-2
[14].
It has been described that the simultaneous pres-
ence of iNOS and arginases, enzymes implicated in
the metabolism of arginine, may play an important
regulatory role, through the control of NO produc-
tion, in LPS-activated J774 mouse macrophages [15].
After initiating the production of NO, macrophages
can su¡er on themselves the toxicity of this radical;
it has been reported that NO induces monocyte/mac-
rophage apoptosis [16,17], through multiple non-re-
dundant signaling pathways [18], where NO is neces-
sary, but insu⁄cient. The existence of speci¢c down-
modulatory mechanisms related to NO-induced
apoptotic DNA fragmentation in murine RAW
264.7 macrophages has been described [19]; and it
has also been observed that cells belonging to this
line can be made resistant to the toxic e¡ects of NO
[20], after treatment with cycles of non-lethal doses
of LPS and INF-Q. This macrophage resistance to-
ward NO-mediated apoptosis is due, at least in part,
to an increased superoxide formation [21]. The apop-
totic signaling cascades converge in the regulation of
caspases; the endogenous NO is capable of down-
regulating caspase-3 by S-nitrosation and oxidation
of critical thiol groups [22]; but the induced apopto-
sis on resistant cells, via exogenous NO donors, has
been found to be caspase-3-independent [23].
We report now that monocytes, entering a process
of activation and di¡erentiation, responded with a
di¡erential expression of mRNAs corresponding to
iNOS and A-II and showed di¡erent arginase and
NOS enzyme activities. An increase in A-II expres-
sion seemed to rescue monocytes from apoptosis,
whereas the down-regulation of A-II, concomitant
with an up-regulation of iNOS, led to apoptosis.
Changes in endogenous NO production induced by
the addition of L-arginine or NMLA resulted in
changes in apoptosis of iNOSA-II monocyte sub-
sets. Results suggest that endogenous NO production
by iNOS, and its down-regulation by A-II in mono-
cyte subsets containing both enzymes, might be in-
volved in the regulation of maturation and auto-
apoptosis in mature hyperstimulated cells.
2. Materials and methods
2.1. Peptide synthesis
Peptide NVLGAPKKLNESQAV, known to have
immunomodulating properties [11,12], and capable
of inducing iNOS in human monocytes [10], was
synthesised by the solid phase method of Merri¢eld
[24].
2.2. Cell sources and cultures
PBMC were obtained from healthy donors, or
from patients with multiple sclerosis or Graves’ dis-
ease or pemphigus vulgaris following the technique
described by BÖyum [25]. Cells were incubated at
1U106 per ml in RPMI-1640 medium supplemented
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with 10% FCS, 2 mM L-glutamine, penicillin (100 U/
ml) and streptomycin (100 Wg/ml) in a 5% CO2 hu-
midi¢ed atmosphere. Isolation and puri¢cation of
monocytes were carried out taking advantage of their
adherence to culture plates. After a period of 4 h at
37‡C non-adherent cells were removed with the
supernatant followed by three washes with saline sol-
ution. Adherent cells, consisting mainly of mono-
cytes, were then carefully detached from the surface
of the culture plates by gentle friction and resus-
pended in a small volume of saline. We considered
as basal state of the monocytes that of adherent cells
after 4 h of culture of freshly isolated PBMC from
patients or from healthy donors before the addition
of peptide Pa. After the ¢rst 24 h of culture, peptide
Pa was added (30 Wg per ml), and 4 h later the
phenotype of the monocytes in the whole PBMC
population, as well as mRNA levels of the enzymes
in the adherent cells were determined; addition of
Pa was reiterated 24 h later and the same analyses
repeated after additional periods of 24, 48 and
72 h.
In another series of experiments we isolated di¡er-
ent subsets of monocytes from adherent cells belong-
ing to PBMC incubated for 72 h in the presence of
peptide Pa. Adherent cells were resuspended in me-
dium culture and then CD14 and CD143= mono-
cytes were separated with magnetisable polystyrene
beads coated with a primary mononuclear antibody
for CD14 membrane antigen (Dynal, Oslo, Norway).
107/ml adherent cells were incubated for 30 min with
2U106/ml magnetisable polystyrene beads at 4‡C and
then centrifugated on a magnetic camp; the subset
having a high CD14 expression remained on the tube
wall forming cell-polystyrene bead complexes, and
the CD143= monocytes could be recovered in the
supernatant.
2.3. Flow cytometry analysis
PBMC were suspended in PBS containing 0.1%
sodium azide at a density of 107 cells per ml. Cells
were incubated with monoclonal antibodies labeled
with FITC or PE: CD14 antibody (Leu-M3)-FITC,
anti-CD16 (Leu-11a)-PE, anti-CD25 (anti-IL-2R)-
PE, anti-CD69 (Leu-23)-PE, anti-HLA-DR-PE,
anti-CD71 (Leu-3a), anti-CD33 (Leu-M9) or anti-
CD23 (Leu-20). Monoclonal antibodies were from
Becton Dickinson. Incubations were performed in
the dark at 4‡C for 30 min. Cells were washed twice
with cold PBS containing 0.1% sodium azide, ¢xed
with 1% paraformaldehyde and stored in the dark at
4‡C until analysis. Fixed cells (20 000 per sample)
were analysed by two-colour £ow cytometry with a
Becton Dickinson FAC Scan £ow-cytometer. Mono-
cytes were gated according to their light scattering
properties; some monocyte subsets exhibited an in-
creased size and granularity, features being re£ected
in the £ow cytometry analysis by their forward and
side light scattering properties. Isotype antibodies of
irrelevant speci¢city were used as negative control.
Speci¢c £uorescence intensity represents the di¡er-
ence between the mean channel of the speci¢c anti-
body and the mean channel of the negative control
antibody expressed on a logarithmic scale. The per-
centage of positive cells was calculated from speci¢c
and non-speci¢c staining. For intracellular iNOS or
TIA labeling, 5U105 PBMC were previously ¢xed
with 4% p-formaldehyde in the dark at 4‡C for
20 min, and then washed with PBS containing 0.1%
sodium azide and suspended in 50 Wl of permeabili-
sation bu¡er (PBS with 0.1% sodium azide, 1% heat-
inactivated FCS and 0.1% saponin). Cells were incu-
bated with anti-TIA-FITC or with anti-iNOS anti-
body (Transduction Laboratories, Lexington, KY,
USA), 1:10 diluted, or IgG-FITC (Becton Dickin-
son) as control at 4‡C for 45 min, washed with per-
meabilisation bu¡er, suspended in PBS and analysed
by £ow cytometry, the small and large monocyte
areas gated according to the pattern of light scatter.
Expression of markers and iNOS or TIA was classi-
¢ed as high (++), low (+), absent (3), or intermedi-
ate (++/+ and +/3), according to £uorescence inten-
sity related to protein expression.
The simultaneous detection of DNA stainability
by PI and annexin V binding was analysed by two-
colour £ow cytometry, using an apoptosis detection
kit (R and D Systems, Minneapolis, MN, USA).
Cells (106/ml) were resuspended in 100 Wl of binding
bu¡er (HEPES bu¡ered saline solution supplemented
with 2.5 mM Ca2Cl) and labeled with 10 Wl of an-
nexin V-FITC and 10 Wl of PI for 15 min to deter-
mine phosphatidyl serine exposure to the outer face
of the cell membrane. Cells were then diluted in
600 Wl of binding bu¡er and immediately analysed
by £ow cytometry gating on the monocyte popula-
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tion. This method permits to distinguish three types
of cells: live cells, not staining with either £uoro-
chrome, necrotic cells, staining with both, and cells
undergoing apoptosis, staining only with the annexin
V-FITC. Values of log of £uorescence intensity less
than 0.5U102 were considered to represent a low
annexin V binding, and values of log of £uorescence
intensity less than 101 were considered to be low for
DNA stainability by PI.
2.4. mRNA analysis of iNOS and type I and II
arginases
For the preparation of RNA, adherent cells were
collected by centrifugation, pelleted cells immediately
disrupted, and RNA extracted using the commercial
kit ‘Total RNA Isolation Reagent’ (Biotecx Labora-
tories, Houston, USA) with the lysis bu¡er ‘Chasolv’
containing guanidinium isothiocyanate following the
manufacturer’s instructions. Total RNA recovered
was treated with RNase-free DNase by standard
methods [26], precipitated with absolute ethanol
and resuspended in water. For cDNA synthesis 1 Wg
of RNA was incubated at 90‡C for 3 min and chilled
on ice for 3 min. Samples were then incubated at
42‡C for 1 h after adding 10 U of RNAsin, 1 mM
deoxynucleoside triphosphates, 200 U M-MLV re-
verse transcriptase (Gibco BRL, UK), 100 pmol of
random hexamers as primers and 4 Wl of 5Ureverse
transcriptase bu¡er (125 mM Tris-HCl, pH 8.5,
15 mM MgCl2, 325 mM KCl) to give a ¢nal volume
of 20 Wl. After the incubation, the reaction was heat-
inactivated at 75‡C for 5 min, and cDNA frozen at
320‡C until use. Dilutions (1:10 to 1:1000) of each
cDNA sample were prepared and a PCR carried out
from each dilution in order to determine and select
the exponential phase conditions for the ampli¢ca-
tion: conditions where the reaction proceeds linearly
before reaching the plateau, so that the amount of
PCR product obtained would re£ect the amount of
starting cDNA, which in turn re£ects the amount of
mRNA in the original sample [27]. All PCR reac-
tions were carried out in 0.2 ml thin wall tubes
with an OmniGene Thermal Cycler (Hybaid) at a
¢nal volume of 20 Wl. The reaction mixture contained
1 Wl of the cDNA dilution, 20 pmol of each speci¢c
primer, 0.2 mM deoxynucleotide phosphates, 2 Wl of
10UPCR bu¡er (100 mM Tris-HCl, pH 9.0, 500 mM
KCl, 1% Triton X-100) and 1 unit of DNA polymer-
ase from Thermus brockianus ‘Dynazime’ (Finn-
zymes). After an initial period of 5 min at 95‡C,
35 cycles of denaturation (95‡C for 30 s), annealing
(Ta 60‡C for 30 s) and extension (72‡C for 30 s) were
performed, ending with a single ¢nal incubation of
5 min at 72‡C. Electrophoresis of PCR products was
performed on 1% agarose gels containing 1 Wg/ml
ethidium bromide. Stained gels were photographed
and optical density (O.D.) of each band measured
by densitometric scanning, subtracting the back-
ground from an equivalent empty area of the gel
picture. A fragment of L-actin mRNA was ampli¢ed
in each sample as an internal normalisation standard
and linear conditions were also determined for this
reaction. The relative amount of each mRNA was
expressed as the O.D. value obtained in linear phase
conditions divided by the O.D. value obtained for
the L-actin mRNA in the same sample, determined
also in linear phase conditions. For iNOS ampli¢ca-
tion a commercially available amplimer set (Clon-
tech, Palo Alto, CA, USA) giving a 259 bp fragment
was used. Arginase I primers (sense: 5P-CTTGT-
TTCGGACTTGCTCGG-3P ; antisense: 5P-CACTC-
TATGTATGGGGGCTTA-3P) were designed from
the described sequence [28] giving a 330 bp product.
Arginase II primers (sense: 5P-TCTATGACCAACT-
TCCTACTC-3P ; antisense: 5P-CTTCTGACTACTC-
CCCACTT-3P) were designed from the described se-
quence [29] giving a 660 bp product. These primers
were designed from non-homologous region between
both isoforms. Sequencing of the PCR products was
conducted to con¢rm the identity of each mRNA in
an ALF automatic laser £uorescent apparatus (Phar-
macia).
2.5. Measurement of arginase activity
Arginase activity was measured in monocyte ly-
sates as described [30]; 106 adherent cells from
PBMC cultures in the presence of Pa were lysed
with 0.5 ml of 0.1% Triton X-100, and after 30 min
0.5 ml of a 25 mM Tris-HCl and 5 mM MnCl2, pH
7.4 bu¡er added. The arginase activity was activated
by heating for 10 min at 56‡C; 25 Wl of the activated
lysate (containing 2 a 10 Wg of protein) were incu-
bated with 25 Wl of 0.5 M arginine, pH 9.7 at 37‡C
for 1 h. The reaction was stopped with 400 Wl of an
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acidic mixture (H2SO4, H3PO4 and H2O, 1:3:7 v/v)
and the urea measured at 540 nm after addition of
25 Wl of 9% K-isonitrosopropiophenone, dissolved in
100% ethanol, and then heating at 100‡C for 45 min.
One unit of arginase activity was de¢ned as the
amount of enzyme catalysing the formation of
1 Wmol urea/min. A calibration curve for urea was
used in the range of 0.05 to 1 Wmol.
2.6. Determination of nitrite/nitrate and NO synthase
assay
For the determination of nitrites and nitrates,
spontaneous degradation products of nitric oxide, a
commercial kit was used (Alexis Corporation, La«u-
fel¢ngen, Switzerland). Photometric measurement
was carried out at 540 nm. Assays were performed
on samples containing 2U106 lymphomononuclear
cells previously disrupted by means of a Parr
bomb. An aliquot of the incubation medium was
used as reaction blank.
NOS activity was determined by measuring the
formation of 3H-L-citrulline from 3H-L-arginine as
described [31]. Reactions were conducted at 37‡C in
50 mM Tris-HCl, pH 7.4, containing 50 WM L-argi-
nine (approximately 300 000 cpm of [2,3,4,5-3H]-L-
arginine HCl; 70 Ci/mmol; Amersham Corp. IL,
USA), 100 WM NADPH, 10 WM tetrahydrobiopterin
and 2^10 Wg protein from monocytes. Enzymatic re-
action was initiated by the addition of the protein
extract and after 1 h ¢nished with the addition of
2 ml of ice-cold bu¡er (20 nM sodium acetate, pH
5.5, containing 1 mM L-citrulline, 2 mM EDTA and
2.0 mM EGTA). L-citrulline was determined by mon-
itoring the formation of 3H-L-citrulline from 3H-L-
arginine; samples of 2 ml were applied to 1 cm di-
ameter columns containing 1 ml of Dower AG50W-
X8, Na form; the £uid eluted was collected in a
liquid scintillation vial and columns washed with
2 ml of water and collected in another vial. Ten ml
of Aquasol-2 were added to each vial and samples
were counted.
2.7. Statistical analysis
Data were analysed using ANOVA and Fisher’s
PLsD tests. A P value less than 0.05 was considered
to be signi¢cant.
3. Results
3.1. Phenotype of monocytes
An analysis of monocytes was carried out after
incubating separately PBMC belonging to three dif-
ferent healthy subjects in the presence of peptide Pa
for up to 5 days. Samples were analysed every 24 h
and two additions of Pa were made at 24 and 48 h
after initiating the culture. Adherent cells, mainly
monocytes, recovered from the incubated PBMC
from healthy donors, or fresh cells from ¢ve patients
with multiple sclerosis, four with Graves’ disease,
and three with pemphigus vulgaris were detached
by gentle friction, after removing the supernatant
containing non-adherent cells. We observed the co-
expression of CD14 and speci¢c activation or di¡er-
entiation surface markers, CD25 (IL-2 receptor),
CD69 (signal transducing receptor), CD71 (transfer-
rin receptor), or CD23 (low-a⁄nity receptor for
IgE), as well as the co-expression of the early mye-
lomonocytic antigens CD33 and CD71, using two-
colour immuno£uorescence analysis. The higher or
lower proportion of monocytes (CD14 expressing
cells) co-expressing the di¡erent markers, as well as
the density of marker per cell, obtained for each
sample during the incubation, are a re£ection of
the di¡erent subpopulations present, i.e. of the evo-
lution of the monocytes. The 30 samples studied were
grouped into four states (A through D) according to
the characteristic pro¢le of the subpopulations
present. In each panel of Fig. 1 (A, B, C, D) the
characteristics of the group are indicated, giving the
mean of the percentage of the di¡erent monocyte
subsets (CD14 expressing cells), co-expressing
HLA-DR or a surface marker. In some samples we
observed the existence of two subpopulations di¡er-
ing in size and granularity, features being re£ected in
£ow cytometry analysis by their forward and side
light scattering properties.
The predominant basal non-activated population,
state A (Fig. 1A), was CD14DR (approximately
50% of all monocytes) and 38% of the monocytes
belonged to the CD14DRsubset, whereas the
CD14DR and CD14DR subsets were practi-
cally absent. The number of monocytes co-expressing
CD16 was very low. The majority of immature
CD14 monocytes exhibited a low expression of
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Fig. 1. RT-PCR analysis of A-I, A-II and iNOS gene expression on monocytes of 30 samples grouped into phenotypes (A^D), as
shown in Fig. 1. Graphics represent the mean of the normalised O.D. for each mRNA band obtained by densitometric analysis
(mean þ S.D.; n = 6 for panel A; n = 8 for panels B, C and D). Normalisation was done dividing each O.D. value by the value of the
L-actin band in the same sample. All PCR reactions were performed in exponential phase conditions. Photographs show a representa-
tive example of the PCR product of each gene in each monocyte state. M, molecular weight marker (PX-174 DNA digested with
HaeIII), iNOS (259 bp), A-I (330 bp) and A-II (660 bp) and L-actin (350 bp).
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the marker of early stimulation CD25, and very
few monocytes expressed CD69; CD23 expression
was very low, so that only 3% of the monocytes
had the CD14CD23 phenotype. No CD14-
CD71 monocytes (data not shown) were found.
A large number of monocytes (85% of all monocytes)
presented a high expression of CD33, and most of
them (70%) co-expressed low levels of CD71, their
phenotype being represented by CD33CD71.
These results indicate that monocytes in state A be-
longed to an immature, non-activated population
(Fig. 1A).
After activating the cells by incubation in the pres-
ence of peptide Pa, ¢ve samples obtained on the
second or third day of culture of PBMC from
healthy donors and other ¢ve samples from patients
(state B) presented a phenotype corresponding to
activated monocytes (Fig. 1B). In this state the pre-
dominant subset was CD14DR (80^90%); the
number of monocytes expressing CD16 increased
slightly with respect to state A. Similarly, the number
of cells expressing CD25 and CD69 increased, mak-
ing the most abundant subsets those with phenotypes
CD14CD25 (65%) and CD14CD69 (43%).
In contrast, only a slight expression of CD23 could
be detected. About 50% of monocytes expressing
CD33 were CD71CD33, indicating that in the
evolution from state A to state B a high proportion
of CD33 monocytes changed from CD71 into
CD71 monocytes.
In more advanced states in the evolution of mono-
cytes induced by peptide Pa (state C, corresponding
to samples taken after 2^4 days of incubation, and
state D, corresponding to samples taken after 3^
5 days), and on fresh monocytes from patients, we
observed the existence of two subpopulations di¡er-
ing in size and granularity, features being re£ected in
£ow cytometry analysis by their forward and side
light scattering properties. Small monocytes were
more abundant in state D than in state C, and
both had a similar phenotype (Fig. 1C and D):
they expressed CD16 on CD14 monocytes, and
high levels of HLA-DR both on CD14 and
CD14 cells. The small monocytes with a
CD14CD16DR phenotype co-expressed high
levels of CD25 and CD69 in state C, and low levels
of both markers in state D. Within this population of
small monocytes we found a subpopulation consist-
Fig. 2. Phenotypes of human monocytes in di¡erent states of
activation and di¡erentiation. Fresh monocytes were obtained
from 12 di¡erent patients with autoimmune diseases. Mono-
cytes were also obtained after incubation of PBMC from three
di¡erent healthy subjects; in this latter case the incubation was
carried out in the presence of immunomodulating peptide Pa,
withdrawing samples after di¡erent periods of incubation (see
details in Section 2). Panels A^D group the phenotypes into
four monocyte states. Data represent the mean of the percent-
age of monocytes co-expressing CD14 and CD16, CD25,
CD69, CD23 or HLA-DR; and that of those co-expressing
CD33 and CD71 (n = 6 for panel A; n = 8 for panels B, C and
D).
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ing of CD14DR, which co-expressed high levels
of CD25 and CD69 in states C and D, and only co-
expressing CD16 and CD23 in state D. However,
large and granular monocytes were almost exclu-
sively CD14 and co-expressed CD16, CD25 and
CD69 and very high levels of HLA-DR. CD14
monocytes co-expressed higher levels of CD16 and
CD23 in state D than in state C. The total number
of monocytes expressing high levels of CD71 in-
creased from about 25% in state A or B to about
50% in state C, and 85% in state D, whereas the
number of monocytes expressing high levels of
marker CD33 decreased when passing from state A
to state D (data not shown). Fig. 1 shows also that a
small percentage of monocytes in state C had a
CD71CD33 phenotype, a phenotype practically
absent in state D.
3.2. iNOS, A-I and A-II mRNA expression, arginase
and NOS activities, and iNOS protein detection
on activated and mature monocytes
To ¢nd out if iNOS and arginases were selectively,
or preferentially, associated with certain monocyte
subsets, adherent cells were analysed for iNOS, A-I
and A-II mRNA expression by RT-PCR in each of
the 30 samples, with the characteristic phenotype of
states A, B, C and D, after linear conditions for PCR
were determined. A fragment of L-actin mRNA was
ampli¢ed in each of the 30 samples as an internal
normalisation control; also for this reaction linear
conditions were determined. Fig. 2 shows a represen-
tative example of RT-PCR gels of the mRNAs ana-
lysed, together with the mean of the O.D. values for
each mRNA, normalised with respect to that of
L-actin ampli¢ed for the same sample. No signi¢cant
di¡erences in A-I mRNA were observed on mono-
cytes in any of the four states, indicating that the
expression remained constant during the incubation
period, in contrast with the variations observed for
the mRNA corresponding to either A-II or iNOS.
Table 1 shows the changes in expression of these
two latter mRNAs with respect to A-I mRNA in
the monocytes analysed. In state A, A-I and A-II
mRNA had a similar expression, and iNOS mRNA
expression was practically non-existent (Fig. 2A).
A-II mRNA reached its maximum value in state B
(Fig. 2B). Monocytes in state C maintained the ex-
pression levels of mRNA corresponding to A-I and
iNOS, already detected in state B; however, a signi¢-
cant fall in the level of A-II mRNA (Fig. 2C and
Table 1) took place. Strikingly, monocytes in state
D expressed iNOS mRNA in high levels (Fig. 2D
and Table 1).
We looked also for possible positive or negative
correlations between each mRNA and the propor-
tion of the di¡erent monocyte subsets; r values
are given in Table 2. A-I seemed to be associated
(Table 2) with the immature CD14 monocyte sub-
set, which practically did not express CD71 nor
CD23; whereas A-II would be associated with the
more activated CD14 monocytes, co-expressing
CD33CD71 (r = 0.5). Taken together, these
data permit to associate the induction of the expres-
sion of A-II with the early activation of monocytes.
Mature monocyte subsets, characterised by the co-
expression of CD16 and DR, could be associated
with the expression of iNOS, in agreement with
data in Table 2.
We determined also the arginase and NOS activ-
ities on 5U106 monocytes belonging to samples in
states A and B obtained after incubation of PBMC
from two new donors. Adherent cells were obtained
and lysed, and formation of urea determined. A
higher arginase activity was detected on samples in
state B than in samples in state A (Table 3); a slight
basal arginase activity was detected in samples lack-
ing A-II mRNA, probably due to the activity of
constitutive A-I.
To ascertain if iNOS was present in both subpop-
ulations of CD16 mature monocytes (small and
large) in state D we looked for iNOS protein using
Table 1
mRNA values of A-II and iNOS relative to A-I mRNA in states A, B, C and D in the evolution of monocyte subpopulations
mRNA State A State B State C State D
A-II/A-I 0.9 þ 0.2 3.4 þ 0.8 1.1 þ 0.3 0.82 þ 0.3
iNOS/A-I 0.2 þ 0.1 0.9 þ 0.2 0.75 þ 0.2 2.6 þ 0.9
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£ow cytometry. We carried out a series of experi-
ments incubating PBMC, from other three healthy
donors, for 5 days in the presence of peptide Pa
and also we analysed fresh monocytes from three
patients. Fig. 3 shows the histograms of a represen-
tative sample; total monocytes co-expressing CD16
were either CD14 or CD14 and they were also
iNOS or iNOS, as the existence of two areas with
di¡erent £uorescence intensities indicated; when the
largest ones were gated it was seen that the predom-
inant subpopulation of monocytes were
CD14CD16 and contained high levels of iNOS
protein; the subpopulation of small monocytes,
which contained all the CD14CD16 cells, besides
some CD14CD16 cells, co-expressed also iNOS
protein. The relative proportion of both monocyte
subpopulations in the six samples analysed was 30^
35% of large CD14 iNOS cells and 70^65% of
small CD14= iNOS cells.
We selected and analysed comparatively ten sam-
ples (¢ve from healthy donors, subjected to the re-
quired incubations, and other ¢ve from patients), all
of them characterised by the absence of the
CD14CD16 subset, abundance of CD14 mono-
cytes co-expressing CD16 and DR, together with the
simultaneous presence of iNOS and A-II mRNAs. In
¢ve samples iNOS mRNA level was higher than A-II
mRNA (the ratio iNOS mRNA/A-II mRNA was
approximately 2.5) and CD14CD16DR=
was the most abundant phenotype; in the other
¢ve samples the iNOS mRNA level was similar to
that of A-II (the mean of the iNOS mRNA/A-II
mRNA ratio was 0.7) and the most abundant subset
was CD14CD16DR. These data con¢rm that
the decrease in the expression of A-II mRNA con-
comitant with an increase in iNOS mRNA expres-
sion was associated with an increase in CD16 expres-
sion on CD14DR monocytes.
Another series of experiments was carried out to
ascertain if A-II mRNA and arginase activity were
simultaneously present in the iNOS positive,
CD14CD16 subset, and absent in the iNOS
Table 3
Arginase and nitric oxide synthase activities of monocyte subsets in di¡erent states of activation and di¡erentiation
Enzyme activities
Predominant monocyte subset Arginase (mU/106 cells) NOS (pmol/min/mg prot.)
CD14DR (state A) 20^30 not detected
CD14DR (state B) 85^95 6 20
Total CD16DR (state D) 45^53 90^120
Large CD14 (state D) 60^70 75^100
Small CD14=ÿ (state D) 28^35 100^130
Arginase and NOS activities were determined on monocytes belonging to samples obtained after incubation of PBMC. CD14 and
CD14=3 monocytes from samples on state D were separated by their binding to anti-CD14 antibody magnetic balls. 2^10 Wg of
monocyte protein were used in each determination. Activities were measured in triplicates of each sample. Two di¡erent experiments
were carried out to obtain cells in states A and B, and other two for state D, using four di¡erent donors. A basal arginase activity
(approximately 15^25 mU/106 cells) was detected in samples lacking A-II mRNA probably corresponding to A-I.
Table 2
Relationship between the percentage of di¡erent monocyte subsets and the expression of A-I, A-II and iNOS mRNA in total mono-
cytes
Positive cells (% of total monocytes)
mRNA CD14DR CD14CD25 CD14CD69 CD33CD71=3 CD14DR CD14CD16 CD14CD16
iNOS r =30.32 r = 0.14 r = 0.12 r =30.61 r = 0.51* R = 0.50* r = 0.50
A-I r = 0.74* r = 0.43 r = 0.29 r = 0.72* r =30.60 R =30.64 r =30.34
A-II r =30.31 r = 0.65* r = 0.70* r =30.39 r = 0.21 R = 0.32 r = 0.56
mRNA of the di¡erent enzymes was evaluated as O.D. normalised with respect to O.D. corresponding to L-actin mRNA in the same
sample. Results indicate the values of the Spearman’s r for positive or negative relationships.
*P6 0.05.
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positive, CD14=3CD16 subset. Taking advantage
of the di¡erent capacity of CD143= and CD14
cells to adhere to anti-CD14 antibody magnetic balls
we separated both monocyte subsets from approxi-
mately 107 cells adhered obtained from 9.5U107
PBMC. A-II mRNA, arginase and NOS activities
were measured in the samples of both monocyte sub-
sets. Cells complexing with the magnetic balls were
predominantly CD14, contained practically all A-
II mRNA and, as shown in Table 3, the arginase
activity present in the entire population of the mono-
cytes of that sample. However, isolated CD14=3
monocytes did not contain any A-II mRNA, and
had a very low arginase activity (Table 3). Both
monocyte subsets had a very high NOS activity;
and higher in CD14=3 than in CD14 monocytes.
Thus the CD14 monocytes had a higher arginase/
NOS ratio than the CD14=3 cells.
In summary, we identi¢ed a subpopulation of
monocytes in state B, expressing arginase; another
subpopulation formed by large granular monocytes
in state D, expressing high levels of CD14, co-ex-
Fig. 4. Flow cytometry analysis of intracellular TIA and detection of apoptotic or necrotic monocytes by simultaneous reduced DNA
stainability with PI and enhanced annexin V binding on monocytes. Samples are representatives of monocytes on di¡erent states as
grouped in Fig. 1, panels B^D. Sample B: CD14DRA-IIiNOS subset. Sample C: CD14=DRA-IIiNOS= subset.
Sample D: CD14=DRA-II=3iNOS monocyte subsets. Values of iNOS mRNA/A-II mRNA ratios were 0.3, 0.7 and 2.7 re-
spectively. 5U105 PBMC were ¢xed, permeabilised and stained using FITC anti-TIA. 20 000 cells were used in each cytometry analy-
sis of annexin V/PI or for TIA expression on parallel samples. The relative proportions of cells with low or high annexin V binding
and DNA stainability with PI or with high TIA expression are indicated.
Fig. 3. Flow cytometry analysis of cytoplasmic iNOS expression by large and small monocytes, co-expressing CD14 and CD16
markers. 5U105 PBMC were ¢xed, permeabilised and stained using FITC mouse anti-iNOS. 20 000 cells were used in each cytometry
analysis of CD14/CD16 or for iNOS expression on parallel samples. Monocytes were gated into two areas according to forward and
side scatter properties to analyse the large or the small cells. The relative proportions of CD14CD16 and CD14CD16 mono-
cytes (large or small) are indicated.
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pressing simultaneously arginase and iNOS; and a
further di¡erentiated subpopulation of small mono-
cytes, in which the decrease in the expression of ar-
ginase and the increase in the expression of iNOS
would be accompanied by a decrease in CD14. The
enzyme activities correlated with the levels of mRNA
expression.
3.3. Apoptosis of di¡erent monocyte subsets with
di¡erent iNOS and arginase expression levels
We analysed TIA expression and annexin V bind-
ing, together with DNA accessibility to PI, on six
samples from patients with autoimmune disease, al-
ready co-expressing iNOS and A-II on freshly ob-
tained monocytes and on ten samples of monocytes
from cultures of PBMC. Fig. 4 shows the histograms
of representative samples of cells on states B, C and
D with di¡erent iNOS mRNA/A-II mRNA ratios
(values of this ratio were 0.3, 0.7 and 2.7 respec-
tively). Monocytes in state B, with low iNOS
mRNA expression and high level of A-II mRNA,
show a low proportion of total cells stained; approx-
imately 20% of total monocytes had a high TIA ex-
pression and high annexin V binding and low DNA
accessibility to PI. Activated monocytes in state C,
with a higher proportion of iNOS mRNA with re-
spect to A-II, were in a more advanced stage of
apoptosis, manifested by a high TIA expression
and annexin V binding, together with low DNA ac-
cessibility to PI. Monocytes in state D, exhibiting a
high expression of iNOS mRNA and a very low ex-
pression of A-II mRNA, presented a large propor-
tion of necrotic monocytes (annexin V binding and
high DNA accessibility to PI) (Fig. 4), co-expressing
very high levels of HLA-II (data not shown), and
also a large proportion of apoptotic cells (annexin
V binding and low DNA accessibility to PI); a re-
duced number of monocytes in this state D had a
high expression of apoptotic marker TIA (Fig. 4).
A number of large CD14CD16 in state D mono-
cytes, co-expressing both enzyme mRNAs did not
show signs of apoptosis (data not shown). A positive
correlation was found between the number of TIA
monocytes and apoptotic cells.
Finally, we studied also on several samples, with
di¡erent iNOS mRNA/A-II mRNA ratios, the en-
dogenous production of NO, measured as nitrate/ni-
trite, necrosis and apoptosis, determined as annexin
V binding and DNA accessibility to PI and also TIA
expression, when PBMC were incubated for 48 h in
the absence or in the presence of L-arginine, or L-
arginine together with NMLA. Table 4 shows that
incubation induced an increase in NO degradation
products and the number of cells with features of
apoptotic and necrotic cells, more markedly when
L-arginine (0.5 or 1 mM) was added to the incuba-
tion medium of cells with high iNOS mRNA/A-II
mRNA ratio. However, NMLA, an inhibitor of
iNOS, reduced slightly the number of apoptotic
and necrotic cells.
4. Discussion
The results now reported (Figs. 1^3 and Tables 1^
3) suggest that the evolution of monocytes implicated
changes in the expression of at least two enzymes
Table 4
Endogenous NO production and induction of apoptosis and necrosis on monocytes
Treatment (48 h culture) Nitrite/nitrate
(nmol/105 cells)
TIA cells
(% monocytes)
Annexin V PI
(Annexin V PI) (% monocytes)
High
iNOS/A-II
Low
iNOS/A-II
High
iNOS/A-II
Low
iNOS/A-II
High
iNOS/A-II
Low
iNOS/A-II
None 4.5 þ 0.6 1.8 þ 0.4 16^26 2^10 20^30 (23^29) 10^15 (0^1)
0.5 mM L-arginine 10 þ 1 2.1 þ 0.2 40^50 3^9 45^50 (35^40) 10^17 (8^15)
1 mM L-arginine 12 þ 2 2.2 þ 0.4 42^50 8^12 50^58 (38^45) 8^16 (10^14)
1 mM arginine+1 mM NMLA 5.2 þ 0.5 2.1 þ 0.3 28^33 8^10 35^40 (30^40) 8^15 (8^13)
Monocytes from three selected patients with autoimmune disease had a high iNOS/A-II mRNA ratio (1.8 þ 0.4), other monocytes
from three other patients had a low ratio (0.5 þ 0.1). PBMC were incubated for 48 h in the absence or in the presence of L-arginine,
or L-arginine together with NMLA.
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involved in arginine metabolism, A-II and iNOS; A-I
remained practically constant. The more immature,
but activated, CD14DRCD163 monocyte sub-
set expressed arginase A-II mRNA and had a high
arginase activity. Two CD14 subpopulations of
large and small monocytes, co-expressing CD16
and HLA-DR, contained simultaneously arginase
and NOS activities. Finally, a population of small
di¡erentiated monocytes expressing CD16 and char-
acterised by low CD14 and low arginase activity,
together with a high NOS activity, was also found.
These changes are consistent with reports showing
that expression of iNOS [32] is mainly regulated at
the transcriptional level, and also that this enzyme,
as well as arginase II, can be induced with suitable
agents, such as LPS or cytokines [2,6^8]. The in-
crease in the proportion of CD14CD16DR
monocytes, as well as the decrease in the proportion
of CD14 monocytes are in agreement with obser-
vations reported by others [33^35], who consider the
CD14 cells as small mature blood monocytes, and
seemingly having their origin in the maturation of
CD14 monocytes. An evolution of monocytes to-
wards macrophages, similar to that induced by pep-
tide Pa, has also been described as being operative in
patients with multiple sclerosis [13], or Graves’ dis-
ease [36]. Furthermore, a correlation of iNOS, CD16
and HLA-DR has already been described by us [13].
On the other hand, it has been shown that CD69, a
member of the natural killer cell gene complex family
of signal transducing receptors, is constitutively ex-
pressed on human peripheral blood monocytes [37],
and also that a CD69 cross-linking induces strong
nitric oxide production by monocytes [38]. It has
also been demonstrated that the expression of both
transferrin receptor (CD71) and low-a⁄nity type II
membrane receptor for IgE (CD23) increase on
monocytes after stimulation with LPS [39]; in vitro
ligand binding to CD23 induces iNOS expression [40]
and activation of monocytes ensued by NO produc-
tion [41]. Furthermore, it has been reported that ni-
tric oxide is an important mediator in the monocytic
di¡erentiation of U937 cells induced by vitamin E-
succinate, or ¢bronectin [42].
Fig. 4 shows that apoptosis was favoured in some
mature monocyte subsets and necrosis in hyperstimu-
lated cells. Two di¡erent methods, based on £ow
cytometry, were used to determine the proportion
of apoptotic monocytes: an assessment of the expres-
sion of TIA, which has been associated with cyto-
toxic T lymphocytes and responsible for triggering
apoptosis [43], and the simultaneous PI uptake and
annexin V binding [44], signs indicative of the initia-
tion of apoptosis. The observed correlation between
both methods suggests that the quanti¢cation of TIA
expression is a valid way to assess the apoptotic state
of monocytes. Di¡erences in the proportion of
monocytes undergoing apoptosis seemed to be due,
at least in part, to the amount of endogenous NO
produced, which in turn seemed to depend on the
balance of iNOS and A-II, associated with the state
of activation and di¡erentiation of monocytes (Ta-
bles 3 and 4). Apoptosis of CD14 monocytes cor-
related with the decrease in the A-II mRNA/iNOS
mRNA ratio (Fig. 3). The more immature, but acti-
vated monocytes, with high expression of HLA-DR,
lacking CD16 and expressing arginase, were non-
apoptotic cells. However, the more di¡erentiated
monocytes, with low levels of CD14 and expressing
CD16, CD23, HLA-DR, as well as iNOS, showed
signs of apoptosis. The degree of apoptosis could
be related, in turn, to the stage of maturation man-
ifested by the proportion of monocytes with low ex-
pression of CD14, in agreement with the observation
that the down-regulation of CD14 triggers apoptosis,
whereas its up-regulation promotes survival [43].
CD14CD16DR monocytes co-expressing
both enzyme mRNAs seemed to be protected from
apoptosis. Data of Table 4 indicate that the simulta-
neous presence of iNOS and A-II, associated with
this subset in an early state of di¡erentiation and
activation, led to a low production of endogenous
NO. That would be a consequence of the competi-
tion of these enzymes for the same substrate, in
agreement with reports showing that arginase mod-
ulates NO production in macrophages [15]. Under
that circumstance NO-triggered apoptosis would be
kept at bay, in contrast with the situation in which
iNOS was present, and A-II absent. These data agree
with reports of others stating that apoptosis is trig-
gered by NO [16,17,45] and regulated by the forma-
tion of superoxides [46], related, in turn, to the state
of maturation of the monocytes.
The results now presented suggest a physiological
role for the dual pathway of arginine metabolism in
human monocytes: the control of endogenous NO
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production, which would permit the evolution from
immature to di¡erentiated cells, preserving them
from a premature NO-induced apoptosis.
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